Published in Neuropsychopharmacology on April 26, 2017
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep (2017) 0.75
Serotonin and brain function: a tale of two receptors. J Psychopharmacol (2017) 0.75
The definition and meaning of treatment-resistant depression. J Clin Psychiatry (2001) 3.98
Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet (2008) 3.79
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) (2006) 2.07
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport (1998) 2.03
5-HT and mechanisms of defence. J Psychopharmacol (1991) 1.99
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol (2014) 1.82
Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst (2006) 1.80
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A (2012) 1.79
Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry (2009) 1.63
Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer (2004) 1.60
Stuck in a rut: rethinking depression and its treatment. Trends Neurosci (2010) 1.60
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry (2010) 1.55
Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull (2001) 1.53
Human hallucinogen research: guidelines for safety. J Psychopharmacol (2008) 1.33
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biol Psychiatry (2014) 1.32
Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A (2016) 1.32
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology (1997) 1.30
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol (2011) 1.27
Euthanasia requests, procedures and outcomes for 100 Belgian patients suffering from psychiatric disorders: a retrospective, descriptive study. BMJ Open (2015) 1.24
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol (2012) 1.21
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry (2005) 1.16
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol (2015) 1.13
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry (2006) 1.12
Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci (2013) 1.07
L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst (1950) 1.02
'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci (2013) 1.01
[Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]. Experientia (1958) 1.00
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis (2014) 1.00
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry (2016) 0.98
Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis (1960) 0.97
Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) (2006) 0.97
Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962. J Hist Med Allied Sci (2012) 0.96
Serotonin receptor 2A gene and the influence of childhood maternal nurturance on adulthood depressive symptoms. Arch Gen Psychiatry (2007) 0.95
Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol (2005) 0.95
Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry (2012) 0.95
Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology (1996) 0.94
Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs (1999) 0.93
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr (2015) 0.93
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) (2007) 0.92
Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry (1994) 0.92
Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry (2012) 0.90
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol (2015) 0.89
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol (2016) 0.89
The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One (2015) 0.87
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol (2016) 0.86
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol (2016) 0.86
Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry (1992) 0.86
Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One (2012) 0.86
Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology (2004) 0.85
The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med (2016) 0.83
LSD enhances suggestibility in healthy volunteers. Psychopharmacology (Berl) (2014) 0.82
LSD enhances the emotional response to music. Psychopharmacology (Berl) (2015) 0.82
Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. J Psychoactive Drugs (2013) 0.81
Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol (2009) 0.81
European rating of drug harms. J Psychopharmacol (2015) 0.81
Desire for psychological support in cancer patients with depression or distress: validation of a simple help question. Psychooncology (2011) 0.80
Polymorphism of the 5-HT(2A) receptor gene: association with stress-related indices in healthy middle-aged adults. Front Behav Neurosci (2007) 0.80
The Differential Susceptibility Hypothesis: Sensitivity to the Environment for Better and for Worse. JAMA Pediatr (2016) 0.79
Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. J Clin Psychiatry (2009) 0.79
Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol (2016) 0.78
Detecting Bipolar Depression from Geographic Location Data. IEEE Trans Biomed Eng (2016) 0.77
Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment. Neuropharmacology (2014) 0.77
Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res (1996) 0.77
The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Curr Biol (2017) 0.77
Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol (2016) 0.76
Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol (2016) 0.76
Culture as a mediator of gene-environment interaction: Cultural consonance, childhood adversity, a 2A serotonin receptor polymorphism, and depression in urban Brazil. Soc Sci Med (2016) 0.76
THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW. JAMA (1964) 0.76
On some effects of lysergic acid diethylamide (L.S.D. 25) in normal volunteers. J Physiol (1953) 0.75
What has serotonin to do with depression? World Psychiatry (2015) 0.75